RCM
DMAAR

Rivernorth Capital Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Rivernorth Capital Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.7K Hold
417,998
– – ﹤0.01% 419
2026
Q1 		$25.2K Hold
417,998
– – ﹤0.01% 463
2025
Q4 		$78.3K Buy
417,998
+100,000
+31% +$19.4K ﹤0.01% 355
2025
Q3 		$69.1K Buy
+317,998
New +$59.1K ﹤0.01% 342

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Rivernorth Capital Management's DMAAR Position: Q2 2026 in Review

Rivernorth Capital Management held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q2 2026 at 417,998 shares worth $62.7K. The position accounts for ﹤0.01% of the portfolio, ranked #419.

Rivernorth Capital Management first reported a position in DMAAR in Q3 2025 and has held it in 4 quarters since. The position peaked at $78.3K in Q4 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • Rivernorth Capital Management held 417,998 shares of Drugs Made In America Acquisition Corp Rights worth $62.7K as of Q2 2026.
  • Rivernorth Capital Management left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q2 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Rivernorth Capital Management's portfolio in Q2 2026, its #419 holding.
  • Rivernorth Capital Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and has held it in 4 quarters since.
  • Rivernorth Capital Management's Drugs Made In America Acquisition Corp Rights position peaked at $78.3K in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Rivernorth Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.